Corvus Pharmaceuticals
CRVS

$2.58

13.42%

Market Cap: 161M

About: Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical engaged in developing drugs and antibodies that target the critical cellular elements of the immune system. It focuses on the development of immune modulator product candidates to treat COVID-19, T-cell lymphomas, other cancers, and autoimmune diseases. The company's primary product candidate is Soquelitinib (CPI-818), an oral, small-molecule drug that selectively inhibits ITK (interleukin-2-inducible T cell kinase). The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).

Employees: 28

Healthcare Pharmaceutical Preparations

0

Funds holding %

of 6,702 funds

0

Analysts bullish %

of 3 analysts

–

News positive %

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

8% more call options, than puts

Call options by funds: $79K | Put options by funds: $73K

0% more funds holding in top 10

Funds holding in top 10: 1 [Q4 2023] → 1 (+0) [Q1 2024]

2.63% less ownership

Funds ownership: 39.12% [Q4 2023] → 36.49% (-2.63%) [Q1 2024]

5% less capital invested

Capital invested by funds: $33.7M [Q4 2023] → $31.8M (-$1.83M) [Q1 2024]

6% less funds holding

Funds holding: 48 [Q4 2023] → 45 (-3) [Q1 2024]

15% less repeat investments, than reductions

Existing positions increased: 11 | Existing positions reduced: 13

33% less first-time investments, than exits

New positions opened: 6 | Existing positions closed: 9

See Fund Rankings

Research analyst outlook

3 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target

$3.50

36%

upside

Avg. target

$6.17

139%

upside

High target

$8

210%

upside

3 analyst ratings

2 positive

67%

1 neutral

33%

0 negative

0%

Oppenheimer Jeff Jones	210%upside $8	Outperform Maintained	7 May 2024
Mizuho Graig Suvannavejh	36%upside $3.5	Neutral Maintained	27 Mar 2024
Oppenheimer Jeff Jones	171%upside $7	Outperform Maintained	20 Mar 2024

See Analyst Rankings

Financial journalist opinion

Corvus Pharmaceuticals Is Ready To Take Flight

Corvus Pharmaceuticals has shown positive growth and maturity over the past six months, with new leadership and increased clinical trial activity. The company is expanding its label and IP developments, with trials in oncology and immunology, as well as potential partnerships with established therapies. Corvus recently completed a capital raise, securing $30M with potential for an additional $60M through warrants, signaling confidence in their Phase 3 trial and future growth.

Corvus Pharmaceuticals Is Ready To Take Flight

The 2024 Millionaire's Club: 3 Penny Stocks to Buy Now

One of the best ways to spot opportunities in penny stocks to buy is by following insiders. Most notably, insiders who are putting their money where their mouth is.

The 2024 Millionaire's Club: 3 Penny Stocks to Buy Now

Corvus Pharmaceuticals to Present at the Jefferies Global Health Conference

BURLINGAME, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that Richard A. Miller, M.D., president and chief executive officer, and Jeffrey Arcara, chief business officer, will conduct one-on-one meetings with investors and present a corporate overview at the Jefferies Global Health Conference, which is being held in New York from June 5-7, 2024. The Company's presentation will be on Wednesday, June 5 at 3:00 pm ET.

Corvus Pharmaceuticals to Present at the Jefferies Global Health Conference

Corvus Pharmaceuticals, Inc. (CRVS) Q1 2024 Earnings Call Transcript

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS ) Q1 2024 Earnings Conference Call May 6, 2024 4:30 PM ET Company Participants Zack Kubow - Real Chemistry Richard Miller - President and CEO, Co-Founder Leiv Lea - Chief Financial Officer Jeffrey Arcara - Chief Business Officer James Rosenbaum - Senior Vice President of Research Ben Jones - Senior Vice President of Regulatory and Pharmaceutical Sciences Conference Call Participants Jeff Jones - Oppenheimer Graig Suvannavejh - Mizuho Securities Liang Cheng - Jefferies Rosemary Li - Cantor Fitzgerald Operator Good afternoon ladies and gentlemen and welcome to the Corvus Pharmaceuticals' Business Update and Reports First Quarter 2024 Financial Results Conference Call. At this time, all lines are in a listen-only mode.

Corvus Pharmaceuticals, Inc. (CRVS) Q1 2024 Earnings Call Transcript

Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2024 Financial Results

Soquelitinib Phase 1 Randomized Trial in Atopic Dermatitis Enrolling at Multiple Centers; Potential for Early Data Before Year-End 2024

Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2024 Financial Results

Corvus Pharmaceuticals to Provide Business Update and First Quarter 2024 Financial Results on May 6, 2024

Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT

Corvus Pharmaceuticals to Provide Business Update and First Quarter 2024 Financial Results on May 6, 2024

Corvus Pharmaceuticals Announces Pricing of $30.6 Million Registered Direct Offering

BURLINGAME, Calif., May 02, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS) (GLOBAL NEWSWIRE), a clinical-stage biopharmaceutical company, today announced that it has entered into a securities purchase agreement with new and existing investors to raise approximately $30.6 million dollars in aggregate gross proceeds through the sale of shares of its common stock, par value $0.0001 per share (the “Common Stock”) and pre-funded warrants to purchase Common Stock in lieu thereof (the “Pre-Funded Warrants”), and accompanying common warrants to purchase Common Stock (or Pre-Funded warrants in lieu thereof) (the “Common Warrants,” and together with the Common Stock and Pre-Funded Warrants, the “Securities”), excluding the proceeds, if any, from the exercise of the Pre-Funded Warrants and the Common Warrants and before deducting offering expenses.

Corvus Pharmaceuticals Announces Pricing of $30.6 Million Registered Direct Offering

Zacks Investment Research

Here's Why Corvus (CRVS) is Poised for a Turnaround After Losing -25% in 4 Weeks

The heavy selling pressure might have exhausted for Corvus (CRVS) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Here's Why Corvus (CRVS) is Poised for a Turnaround After Losing -25% in 4 Weeks

Corvus Pharmaceuticals Announces Initiation of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

Atopic dermatitis is the first immune disease indication being studied in the clinic for soquelitinib, the Company's selective ITK inhibitor

Corvus Pharmaceuticals Announces Initiation of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

Zacks Investment Research

Down -18.35% in 4 Weeks, Here's Why Corvus (CRVS) Looks Ripe for a Turnaround

Corvus (CRVS) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Down -18.35% in 4 Weeks, Here's Why Corvus (CRVS) Looks Ripe for a Turnaround

See News Rankings